Targanta Therapeutics Corporation: Company Strategy, SWOT Analysis and 5-year Adjusted Financials

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 11-Jun-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Targanta Therapeutics (Targanta) is focused on the development and commercialization of antibiotics for infections treated or acquired in hospitals and other institutional settings. The company's lead product candidate, Oritavancin, is a semisynthetic glycopeptide that targets gram positive infections including methicillinresistant staphylococcus aureus (MRSA).


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    The company discovers other antibiotics that are currently in pre-clinical development for the treatment of osteomyelitis, or infection of the bone in addition to its lead product candidate, Oritavancin.

    The company has not generated any product revenue since its inception. Further, the company has not entered into any revenue-generating collaboration arrangements. The company does not expect to generate any revenue from the sale of products until it receives regulatory approval for the commercial sale of Oritavancin.

    The sole contributor to the company's revenues would be the product sales of Oritavancin in the US and other regions. The company expects to launch this product in the year 2009. The sales from this product are expected to increase from $42 million in 2009 to $172 million in 2011.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: targanta therapeutics swot analysis mrsa gayle analyst price proteins swotaalysisformrsa

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.